Privium Fund Management B.V. Has $12.93 Million Holdings in Biogen Inc. $BIIB

Privium Fund Management B.V. lifted its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 41.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 73,480 shares of the biotechnology company’s stock after purchasing an additional 21,555 shares during the period. Biogen accounts for 2.4% of Privium Fund Management B.V.’s holdings, making the stock its 12th biggest holding. Privium Fund Management B.V.’s holdings in Biogen were worth $12,932,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of BIIB. Orion Porfolio Solutions LLC lifted its holdings in Biogen by 6,828.4% in the second quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock valued at $64,965,000 after buying an additional 509,809 shares during the period. Caisse de depot et placement du Quebec lifted its holdings in Biogen by 718.2% in the third quarter. Caisse de depot et placement du Quebec now owns 569,253 shares of the biotechnology company’s stock valued at $79,741,000 after buying an additional 499,676 shares during the period. AQR Capital Management LLC lifted its holdings in Biogen by 30.7% in the third quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company’s stock valued at $248,809,000 after buying an additional 418,776 shares during the period. Alyeska Investment Group L.P. lifted its holdings in Biogen by 66.1% in the third quarter. Alyeska Investment Group L.P. now owns 845,277 shares of the biotechnology company’s stock valued at $118,406,000 after buying an additional 336,504 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Biogen by 425.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 348,404 shares of the biotechnology company’s stock valued at $48,804,000 after buying an additional 282,084 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Price Performance

Shares of NASDAQ BIIB opened at $189.13 on Wednesday. The firm’s 50-day moving average price is $184.46 and its 200-day moving average price is $176.82. Biogen Inc. has a 1-year low of $115.25 and a 1-year high of $202.41. The firm has a market capitalization of $27.92 billion, a P/E ratio of 20.29, a P/E/G ratio of 1.62 and a beta of 0.19. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The firm had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the prior year, the business earned $3.02 earnings per share. The business’s quarterly revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Equities research analysts anticipate that Biogen Inc. will post 14.41 earnings per share for the current fiscal year.

Insider Buying and Selling at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the transaction, the insider owned 8,043 shares in the company, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.18% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on BIIB shares. Stifel Nicolaus boosted their target price on shares of Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a report on Friday, February 6th. Argus upgraded shares of Biogen to a “hold” rating in a report on Thursday, April 9th. Canaccord Genuity Group boosted their target price on shares of Biogen from $230.00 to $245.00 and gave the company a “buy” rating in a report on Wednesday, April 1st. Royal Bank Of Canada boosted their target price on shares of Biogen from $213.00 to $222.00 and gave the company an “outperform” rating in a report on Thursday, April 30th. Finally, Barclays initiated coverage on shares of Biogen in a report on Thursday, February 19th. They set an “equal weight” rating and a $185.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $214.23.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.